Compare IVT & LQDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IVT | LQDA |
|---|---|---|
| Founded | 2005 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 2.5B |
| IPO Year | N/A | 2018 |
| Metric | IVT | LQDA |
|---|---|---|
| Price | $28.04 | $33.95 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 10 |
| Target Price | $32.00 | ★ $37.40 |
| AVG Volume (30 Days) | 527.9K | ★ 2.0M |
| Earning Date | 10-28-2025 | 11-03-2025 |
| Dividend Yield | ★ 3.40% | N/A |
| EPS Growth | ★ 1421.59 | N/A |
| EPS | ★ 1.51 | N/A |
| Revenue | ★ $293,020,000.00 | $69,216,000.00 |
| Revenue This Year | $9.58 | $904.79 |
| Revenue Next Year | $6.83 | $188.25 |
| P/E Ratio | $18.54 | ★ N/A |
| Revenue Growth | 9.60 | ★ 343.41 |
| 52 Week Low | $25.21 | $10.37 |
| 52 Week High | $31.51 | $34.02 |
| Indicator | IVT | LQDA |
|---|---|---|
| Relative Strength Index (RSI) | 48.34 | 69.52 |
| Support Level | $28.22 | $30.50 |
| Resistance Level | $28.88 | $32.80 |
| Average True Range (ATR) | 0.50 | 1.82 |
| MACD | 0.04 | 0.31 |
| Stochastic Oscillator | 40.97 | 99.22 |
InvenTrust Properties Corp is the United States of America based company qualified as a REIT (Real Estate Investment Trust). It is focused on owning, leasing, redeveloping, acquiring and managing a multi-tenant retail platform. The company's wholly-owned and managed retail properties include grocery-anchored community and neighborhood centers and power centers, including those classified as necessity-based. InvenTrust operates through a single segment i.e. multi-tenant retail.
Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also generates revenue from the sale of Treprostinil Injection through an agreement between its subsidiary and the manufacturer.